CRCorvus Pharmaceuticals, Inc. CRVS · NASDAQ
$10.53 -1.13% (-$0.12)
- Market cap
- $895.9M
- Enterprise value
- $877.7M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -25.5%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.86
- Free float
- 77.0%
About the company
Corvus Pharmaceuticals, Inc. (CRVS) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of various types of cancer. Their primary goal is to discover and develop innovative therapies targeting the immune system that focus on specific immune pathways and interactions between tumors and the host immune system. Among their main products are drugs based on immune checkpoint inhibitors and immune response modulators, which have the potential to improve the treatment of various types of cancer and increase patient survival.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard A. Miller
Employees
37
Headquarters
South San Francisco
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number